GSE165729 p300-CBP inhibition 0 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE165729_p300-CBP inhibition_0_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE165729_p300-CBP inhibition_0_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE165729_p300-CBP inhibition_0_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE165729_p300-CBP inhibition_0_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

dickkopf Wnt signaling pathway inhibitor 1

Gene

adhesion molecule with Ig like domain 2

Gene

gap junction protein alpha 1

Gene

olfactomedin 4

Gene

plasminogen activator, tissue type

Gene

pleckstrin homology like domain family A member 1

Gene

protein kinase cAMP-dependent type II regulatory subunit beta

Gene

stanniocalcin 2

Gene

insulin receptor substrate 2

Gene

thrombospondin 1

  • Gene

    dickkopf Wnt signaling pathway inhibitor 1


  • Gene

    adhesion molecule with Ig like domain 2


  • Gene

    gap junction protein alpha 1



  • Gene

    plasminogen activator, tissue type


  • Gene

    pleckstrin homology like domain family A member 1


  • Gene

    protein kinase cAMP-dependent type II regulatory subunit beta


  • Gene

    stanniocalcin 2


  • Gene

    insulin receptor substrate 2


  • Gene

    thrombospondin 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.